ArticleJournal of cancer research and clinical oncology2026
Radiomics based on multiphasic contrast-enhanced CT combined with clinical features for differentiating hypovascular pancreatic neuroendocrine tumors and pancreatic ductal adenocarcinoma.
Article in Journal of cancer research and clinical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
purposeTo evaluate the value of a combined model based on multiphase contrast-enhanced CT radiomics and clinical features for differentiating hypovascular pancreatic neuroendocrine tumors (hypo-PNETs) from pancreatic ductal adenocarcinoma (PDAC).
methodsA total of 297 patients with pathologically confirmed pancreatic tumors, including 99 hypo-PNETs and 198 PDACs, were retrospectively enrolled. Radiomics features were extracted from non-contrast, arterial-phase, venous-phase, and combined three-phase CT images. After feature selection, radiomics models were established using multiple machine-learning classifiers. Independent clinical predictors were identified by logistic regression and integrated with the optimal radiomics signature to construct a combined model. Model performance was assessed using receiver operating characteristic analysis, calibration curves, decision curve analysis, net reclassification improvement, and integrated discrimination improvement.
resultsPancreatic duct dilatation, tumor composition, age, and maximum tumor diameter were identified as independent predictors. Among the radiomics models, the combined three-phase SVM model achieved the best performance, with AUCs of 0.814 and 0.812 in the training and test sets, respectively. The combined model yielded the highest AUCs (0.886 in the training set and 0.849 in the test set); however, because several between-model comparisons in the test set did not reach statistical significance, its advantage should be interpreted as a potential incremental benefit rather than definitive superiority.
conclusionA combined model integrating multiphasic CT radiomics and clinical features showed promising performance for differentiating hypo-PNETs from PDAC. This model may provide complementary support for preoperative diagnosis, although its incremental value over the radiomics-only model requires further validation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.